An experimental drug under development by Gilead Sciences for hepatitis C is safe and effective when combined with other treatments, according to a review posted on the Food and Drug Administration's website ahead of an expert panel meeting to take place Friday.
When it comes to laws and regulations, what happens in Europe stays in Europe generally, and doesn’t have much bearing on the United States. But a recent win in Europe for U.S. drug maker Hospira could have some implications for the United States as well.
Drug makers have 901 biotech drugs under development for more than 100 diseases ranging from cancers and infectious diseases to autoimmune disorders and cardiovascular diseases, the Pharmaceutical Research and Manufacturers of America said.
A phrase like “silent killer” sounds creepy enough on its own, but it’s an often-used one for a virus that, according to the Centers for Disease Control and Prevention, infects 1.3% to 1.9% of people in the United States.
Medication adherence among hepatitis C patients may improve when patients take antidepressants, according to a new analysis by pharmacy benefit manager Medco Health Solutions presented Monday at the International Conference on Viral Hepatitis.